PPARg-agonists are used to treat type 2 diabetes by redistributing adipose tissue from abdominal visceral to subcutaneous compartment, which is thought to be preferable and improve insulin sensitivity. This evidence concerns the gene PPARG and type 2 diabetes mellitus.